Scientists Simplifying Science

Tag archive

Merck

MedNess Special: Bringing North America, Europe and Asia together

in Medness by

Hello everyone and welcome to MedNess Global! Here at ClubSciWri, we are constantly trying to present the most impactful news in an ever-evolving innovative fashion. In this special edition, we bring business news from pharma and healthcare sectors in North America, Europe and Asia. Know what defines the industry space in each continent. Where is big capital invested on pharma research? And where does the manufacturing happen? What regulations underlie the drug making and selling processes across continents? This is an effort to give our readers a holistic understanding of international collaborations and deals in the industry. We thank our additional team of writers for their input; MedNess North America: Vinita Bharat; MedNess Europe: Czuee Morey; and MedNess Asia: Somdatta Karak

 

We value your input, please do not forget to provide your feedback (Fill the form at the end of this blog). Please subscribe to ClubSciWri (www.sciwri.club) for weekly updates!

MedNess North America

Merck Ventures supported Inthera Bioscience with their $11M investment

Protein-protein interactions (PPIs) are the basis of multiple control points in the body and play a pivotal role in multiple diseases, including cancer. PPI’s serve as the important target classes in oncology but are extremely intractable to work with.  Inthera bioscience, a Swiss based biopharma aims to design oral small molecules which can inhibit these PPIs, leading to the targeted approach for the treatment of solid tumors.  

For this innovative, novel and promising approach, Inthera drew the seed money of $3.8M in 2005, and now once again Merck Ventures invested $10.8M to wrap up pre-clinical developments focusing on HPV-associated cancers and hypoxia-inducible signaling  (FierceBiotech).

MedNess: Inthera Biosciences is a private biopharmaceutical company focussing on PPI’s. Inthera’s research group focuses on HPV-associated cancers and hypoxic signaling. Merck Ventures is the venture capital wing of Merck. This wing invests in novel products and technologies with significant potential to impact Merck’s core research areas (Biospace)

Novartis fully concentrated on its CAR-T cell therapy for “ALL” cancer

Novartis is specifically betting on its CAR-T cell therapy even though acknowledging that there is a gap in the other major I-O driven therapies like, IDO, BTK and PARP inhibitors. CAR-T is patient specific and looks likely to be the first of this new cancer class to reach the market by this fall.

CAR-T cell therapy involves the drawing of T-cells from patient’s blood and then reprogramming it in laboratory to hunt patient’s cancer cells and other B-cells expressing a particular antigen. Novartis touts this week data of its CAR-T candidate, CTL119 which when used with Janssen/Pharmacyclics’ Imbruvica (ibrutinib) gave complete responses with no evidence of disease in the bone marrow at three months (FierceBiotech).

MedNess: Novartis on June 1 opened with 81.78 and closed by 81.86 (Nasdaq.com). Novartis stock price has increased by 12.3% in the last 12 months. According to Zack’s classified, Novartis ranks number 3 and with its innovative technology, the stocks are advised to be hold onto (Zacks.com; TheStreet.com).

 

Tesaro’s new FDA approval med Zejula is waiting for its response

Tesaro’s PARP inhibitor based drug Zejula has one of 2017’s biggest launches, with an estimate of $1.9 billion till 2022. The company requested offers from the potential bidders but seems like they are waiting to hear from them.

Apart from the high price of this drug, buyers seem to wait for ASCO meeting where they can compare the results of Zejula with AstraZeneca’s Lynparza, Merck’s Keytruda and others. Hence, Zejula clealry opens up a PARP market and its big response is now relying on its ability to rack up new indications in prostate and breast cancer (FiercePharma).

 MedNess Europe

Therapeutic antibody against non-Hodgkin’s lymphoma developed by MorphoSys enters Phase 3 clinical trials

The German biotech MorphoSys announced that its therapeutic antibody, MOR208, has entered Phase 3 clinical trials after successful completion of the phase 2 part of the combined phase 2/3 trials. The randomized, multicenter phase 2/3 study is designed to investigate the efficacy of MOR208 plus bendamustine versus rituximab plus bendamustine in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), the most common form of non-Hodgkin’s lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.

MOR208 is an Fc-enhanced monoclonal antibody that targets CD-19 homogeneously expressed on the surface of all B-cells. MOR208 is intended to induce direct apoptosis by binding to CD-19 along with significant potentiation of antibody-dependent cell-mediated cytotoxicity and cellular phagocytosis, thus aiming to improve a key mechanism of tumor cell killing.

MOR208 can therefore be useful to treat various B-cell malignancies such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL). Each year about 150,000 people are afflicted by B cell malignancies in the seven major markets. MOR208 was granted orphan drug designation in DLBCL and CLL across US and Europe. Additionally, the FDA has granted fast track designation for the treatment of DLBCL. MOR208 is under investigation in a separate clinical trial for CLL.

The dosing of the first patient in the phase 3 part will trigger an undisclosed milestone payment to Xencor, Inc., from whom MOR208 was in-licensed in 2010. MorphoSys has worldwide rights to MOR208. If this clinical trial is successful, MOR208 will be the first therapy that MorphoSys develops in clinical trials independently. However, MorphoSys has had a lot of success with its Human Combinatorial Antibody Library (HuCAL) that generates human antibodies in bacteria, after having been screened with the aid of specific phages. In partnership with Big pharma companies, MorphoSys has funneled over 100 monoclonal antibodies into the clinic with this platform (Labiotech.eu, Morphosys website).

MedNess Asia

Mismatch between FDA regulations and its implementation in Chinese API manufacturing companies

Cheaper manufacturing processes in China and India attract pharma companies in getting their Active Pharmaceutical Ingredients (APIs) manufactured for cheap in Asia. However, the manufacturing companies have to comply with regulations of the country where the drug is sold and intended to be used. Of the companies facing non-compliance with this are Chinese API makers, Teva Pharmaceutical Industries and Changzhou Jintan Qianyao Raw Material Factory failed US FDA inspection and has consequently been banned to ship all their products to the USA. The company had failed to meet with the Good Manufacturing Practice (GMP) expectations from  the US FDA. (GEN, FiercePharma)

MedNess: China is currently the world’s leading producer of pharma ingredients, covering 40% of global production, primarily because of the price advantage that they offer. It will be interesting to see if the API companies are willing to increase their costs by adding more regulatory expenses or let go of the multinational companies. On the other hand, China FDA (CFDA) has tightened its regulations to stop sub-standard operations.

Pricing pressures and non-compliance with US FDA regulations make difficult times for Sun Pharma

At the end of FY2016, Sun Pharmaceuticals Ltd., India’s largest pharma company, took a hit in its US sales for numerous reasons. Its key API maker for the US market, Halol faces US FDA regulatory limitations since 2014. US FDA slammed Halol with warning letters twice for reasons from inadequate data protection on computer to possibilities of contamination in their products despite Sun seeking help from consultants to make the plant US FDA compliant. In addition, Sun faces pricing pressure like the other generic drug companies. In addition, its US subsidiary specialty generics drugmaker, Taro faced a 26% drop in their sales.

More than 70% of Sun’s sales are from outside India, with US contributing to 50% of its turnover. With multiple worries continuing, Sun’s Managing Director Dilip Sanghvi has warned of single digit declines in the FY2018 revenues. (FiercePharma, Business Standard)

MedNess: Over the last 6 months Sun Pharma has seen a 28% drop in its stock prices (NSE). While resolving US FDA warning letters can take long, generic drugs pricing pressures might bring more mergers and acquisitions in the field.

 

China’s steps beyond generic drug making in healthcare sector

Founded in 2012, in Beijing, privately-held and venture-capital (VC) backed, CANbridge Life Sciences Ltd. has paved its path towards developing leading candidates in solid-tumor oncology, primarily in China, Taiwan and Korea by gathering funding worth $40mn, together after its second round of funding. Currently it focuses on two of its prime compounds – CAN008 and CAN017, and the former is already in phase I/II trial for glioblastoma multiforme, in Taiwan and will begin its phase II in China in 2018. CAN017 is designed against esophageal squamous cell cancer – the most prevalent form of cancer in Asia and has already been successful in phase I study in Greater China. CANbridge partners with AVEO Oncology (for the rights on the compounds) and Böhringer Ingelheim (for manufacturing) in development of CAN017. CANbridge talks of plans of more strategic transactions in 2017 – backed by strong finances and executive team – in direction of developing specialty healthcare products.  (Fierce Biotech, Biospace)

MedNess: China’s huge aging population and increase in lifestyle disorders as well as growth in per capita earning and expenditure is a promising ground to get into specialty healthcare products in China. CANbridge is an interesting example to study commercialization of healthcare products that are under-served in China and North Asia, by partnering with its developers and manufacturers in western countries. Since CANbridge is still VC backed, stocks are not yet for sale.

 

 

Featured Image by: Vinita Bharat

 

 

 

 

 

 

 

About the authors:

 

 

 

 

 

 

Imit Kaur, Ph.D. is a freelance scientific advisor, medical writer, editor, and an active science blogger. She pursued her PhD in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah. She is experienced in the field of oncology, hematology, pharmacology, nanotechnology and drug development. Follow Imit on LinkedIn (Imit Kaur) or Twitter (@imit_kaur)

 

 

 

 

 

 

Somdatta Karak, PhD is interested in pharma and healthcare sector in Asia. She also works with PhD Career Support Group / Club SciWri as its project coordinator. She aims to make a more and better informed world for all, and hence experiments with making effective platforms of education. She can be reached here.

Czuee Morey has a PhD from University of Lausanne and pursued a postdoc from University of Geneva. She has broad interests in healthcare and technology as evidenced by her research experience in fields such as protein biophysics and genomics. She has previously worked as a patent analyst and also built the business plan for her startup project. She is currently working in market intelligence for digital healthcare at Debiopharm in Lausanne, Switzerland.

Vinita Bharat Ph.D., is currently a postdoctoral research fellow at European Neuroscience Institute, Göttingen, Germany and had been an International Max Planck Research School (IMPRS) student here. Her research area focuses on cellular and molecular neuroscience. Other than enjoying ‘being a scientist’, she has also been working on science education. Presenting science in easy and fun way is what she loves doing through her platform “Fuzzy Synapse” (one can find fuzzy synapse on Facebook, Instagram and Twitter). She is a fun, enthusiastic and curious person, passionate about traveling, loves celebrations and bringing smiles around her.

© The contents of Medness are the copyright of the PhD Career Support Group for STEM PhDs (A US Non-Profit 501(c)3, PhDCSG is an initiative of the alumni of the Indian Institute of Science, Bangalore. The primary aim of this group is to build a NETWORK among scientists, engineers and entrepreneurs)

Blog design: Abhinav Dey

Creative Commons License
This work by ClubSciWri is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

MedNess: Healthcare Business News from the Month of May

in Medness by

Hello everyone and welcome to MedNess: At the frontier of healthcare news. I am back with the news from healthcare business that had the most impact this month Read below to find out more.

 

To stay on top of scientific advancements, subscribe to Club SciWri (www.sciwri.club)

Neurotrope’s Alzheimer’s candidate fails to yield statistically significant results

Earlier this month Neurotrope reported results from its Phase 2 Alzheimer’s study of Bryostatin. The trial involving 147 patients with moderate to severe Alzheimer’s met its primary endpoint in patients that completed the full course of treatment. Bryostatin improved outcomes in cognition and ability to handle daily activities but failed to achieve statistical significance over placebo (FierceBiotech).

Neurotrope is hopeful of its candidate and plans to take the study forward.

MedNess: This is yet another Alzheimer’s candidate that failed in Phase 2 testing. The successful treatment of dementia is an enigma, and most drug candidates fail larger phase 2 trials. No new drug has been approved for Alzheimer’s for more than a decade. Neurotrope’s shares fell by 63% (Biospace)

Moderna Therapeutics reports interim Phase 1 results from mRNA based H10N8 flu vaccine

The private biotech company; Moderna Therapeutics reported positive interim results from phase 1 study of mRNA-1440 vaccine against avian H10N8 flu. The complete data and results were published in the journal Molecular Therapy.

31 subjects were enrolled in the Phase 1 study, and 23 received 100 µg of the vaccine. All participants achieved HAI titers suggesting seroprotection against seasonal flu. No response was achieved in the placebo arm (8 subjects). (FiercePharma)

MedNess: Since the company is still private, the only investment that can be made in Moderna Therapeutics is through venture capital funds. The company’s valuation is $3B, and primary sources of funding are grants and private investments (Investopedia and The Motley Fool).

Sanofi against affordable pricing for Zika vaccine

Sanofi Pasteur, the leader in vaccine manufacture, was under fire by US army officials and Senator Bernie Sanders after refusing the US Army’s plea for affordable US price for a Zika virus vaccine. Sanofi boasts of about $43 million US research grant money. Sanders and lawmakers have been requesting the US Army to reconsider its term of negotiations with Sanofi that could provide the latter an exclusive license to make and sell Zika vaccine in the US. The vaccine is being developed with the American taxpayer funds, thus prompting both the US Army and Sanders to request an affordable price for the American population.

The spokesperson from the Army states that the decision to provide Sanofi an exclusive licensing is still under consideration and the final decision will be made in the summer (STAT).

Corbus Pharma’s anabasum denied BTD for systemic sclerosis; enrolls the last patient for mid stage-study dermatomyositis

Corbus Pharma’s anabasum (Resunab) was previously provided Orphan Drug designation for Fast Track review by the FDA for systemic sclerosis. However, this month Corbus Pharmaceuticals was trying to gain Breakthrough Therapy status for the drug. The plea was rejected by the FDA. The BTD designation entails recurrent meetings with senior personnel and a rolling review of the New Drug Application. Meanwhile, in another phase 2 clinical trial where anabasum is being tested for dermatomyositis, the last patient was enrolled

MedNess: The failure to gain BTD designation by the FDA worried the investors, slipping shares down by 12%. However, with the news of last patient enrollment, the shares moved up by 3%.

The Belgian-Dutch Biotech Argenx draws $115M post-IPO filing

Argenx filed for IPO last month to draw cash from American investors; in order to push its lead candidate ARGX-113, an antibody directed against autoimmune disorders myasthenia gravis and primary immune thrombocytopenia, to phase 3 trials. It also proposed moving its lead cancer candidate ARGX-110 through mid phase studies. The biotech was able to rope in $115M, 50% above its target goal of $75M.

The biotech started their phase 2 studies with ARGX-113 earlier this year, and the results are expected in the first quarter of next year. A 30% drop in the IgG antibody level would be considered clinically significant (Fierce Biotech, Market Watch).

Incyte reports positive results from selective IDO1 enzyme inhibitor, epacadostat in two separate combined trials

Incyte reported first set of positive results from ongoing combined trials; ECHO-202 in combination with Merck (epacadostat+ Keytruda) and ECHO-204 in combination with BMS (epacadostat + Opdivo). The full sets of results will be announced at American Society of Clinical Oncology (ASCO) meeting next month.

The ECHO-202 trial is assessing epacadostat (selective IDO1 enzyme inhibitor) in combination with Merck’s Keytruda (anti-PD1 immunotherapy). The efficacy and safety results from the phase I/II trial showed that epacadostat in combination with Keytruda was well-tolerated in the following cohorts: non-small cell lung cancer, renal cell carcinoma, ovarian cancer, triple-negative breast cancer, bladder cancer, and head and neck squamous cell carcinoma.

Alternatively, data from the ECHO-204 trial evaluating the safety and efficacy of epacadostat, in combination with Bristol-Myers Squibb’s PD-1 inhibitor Opdivo showed the combination was well tolerated in melanoma, head and neck squamous cell carcinoma, ovarian cancer, and colorectal cancer (Incyte.com).

MedNess: Following the positive results, Incyte’s shares gained 2.3%, rose by 6% by mid-day which rose by 8% towards the end of the day (Thursday, May 18, 2017) with the overall increase of 14.10% by the end of the week (Zacks, Investor Place, The Street, and CNN Money).

About the Author:  

Imit Kaur is a freelance medical writer, editor, and an active science blogger. She pursued her Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah. She is experienced in the field of oncology, hematology, pharmacology, nanotechnology and drug development.

Follow Imit on LinkedIn (Imit Kaur) or Twitter (@imit_kaur)

 

 

The week that it was – 15th to 21st May, 2017

in ClubSciWri by
  • 1548034_10152124600876703_839288437_o.jpg?fit=2048%2C1127
    Frost in Northern Iceland (photograph by Somdatta Karak)
Inter-connectedness of scientific research, policy makers, government and public, by IpsaWonders (on Facebook and Instagram)

I can’t help but start this week’s updates with discussing global warming as the Global Seed Vault buried in the Arctic to ensure food supply at the face of a humongous calamity by storing seeds of important crops is under risk as its protective permafrost is melting away. This brings me again to reiterate and emphasize on the importance of science outreach and diplomacy to hit a chord with the statesmen and policy makers. If this is something that makes you want to make a difference, here is your opportunity to get trained by ASBMB, as it invites you to participate in workshop on communication, outreach and professional development at Kentucky, USA on 29th – 30th September, 2017.

Not only just for policies, but you also have the power to tell people the stories of scientific development. Here are a few from plenty that interested the CSG members – Team of scientists from Massachusetts build Institute for Protein Innovation – aim towards developing antibodies against every extracellular proteins in humans, aim to work with non-affiliated industry and academic investigators. In the age of omics, Harvard Medical School researchers are mapping interaction partners in the entire human proteome. A big NIH funding has been granted to study neurobiological gender differences at Worchester Polytechnic Institute. While all these interesting work is happening in the field – should we have more permanent staff scientist positions or hire more PhD students and postdocs, a constantly moving mass of people?

Celebrating the big women scientists, by IpsaWonders (on Facebook and Instagram)

In the conquest of reducing gender gap in science, UNESCO offers PhD fellowships to women scientists from developing countries, generously funded by Swedish International Development Cooperation Agency. Going beyond academia, NITI Aayog celebrates women’s contribution to India’s growth in formal and informal economy – make the powerful women around you known. Mothers can now add their maternal experience on LinkedIn as well – thanks to a tool that Mother NY has developed. But at the heart of the problem , it is of prime importance to recognize our biases, and also to know how to circumvent them – an example to follow from GDI with support from Google to design machine learning to detect how much time females occupy in movies.

And everything somehow these days boil down to data science and machine learning! Who are the people working in machine learning, what skills and expertise do they need to have? Not just in for profit industries, it has the potential to solve complex societal problems like changing the face of education where teachers take up the more roles of mentors, enabling and concentrating on each individual’s growth.Unfortunately, in this era of intense competition, mentoring has taken a back seat in many places, including research. Most of us as early career researchers need a good mentor, the late career researchers should strive to become a good mentor – and for anyone who wants to know what should a good mentor do, here is some advice. Being a good team leader also means being able to nurture good ideas. But unconsciously we tend to kill a lot of these, know how. Here is a piece of dark humor of where a PhD student in India also evaluates himself in absence of university’s efforts to look for mentors for the students it registers.

Fortunate are the ones who master the art of staying open to diverse possibilities – see what three different PhD holders have to say on this, a personal account of how time spent in academia also prepares you for other careers. And for the ones who are the path of learning here are some tips to boost your career. Stay visible to recruiters via LinkedIn – here are some numbers to coax you into networking. It’s equally important to know what and how not to speak while presenting yourself.

If you are confused about what skills are required for the jobs in market, I am here with some help for you. Find all that you need to know about consulting and entry into data science as a PhD holder. What is medical writing? What does it mean to be a website and social media manager at CIRM? Hear Leslie Stolz, Head of Johnson & Johnson Innovation speak at JLABS, LA, about her experience as a business development professional – what, how and why do they know to take the ‘right’ decisions for their companies. There is an upcoming workshop on combating antimicrobial resistance at Washington, DC, USA from June 20-21, 2017. If you are moving into the USA, it will help you to have immigration info relevant for APD holders.

Know the companies trending currently – here is CNBC’s top 50 disruptor companies of 2017. Let’s a take a sneak peek into the other big names. What does Abbvie aim towards? Amazon is beginning its entry in pharma and life science industries. Novartis is reshuffling jobs in different continents as it heads for more centralization. Sanofi invites proposals for cancer treatment via precision medicine. It might help you to stay updated with the latest developments in the field of precision medicine by the essays published by JAMA on the field.

I have a good reason to have you prepared you with all this bits of information so far – this week has a bonanza of job openings in the USA and Europe. Check which one fits and suits you.

Also know the pros and cons of contract based positions in life science industries – it is certainly a trend on a rise! For people who consider freelance working or starting up a new enterprise you are then one of the multipotentialites – those who know how to do everything – here is a story of one of them to pep you up.

And here is my summer challenge to get you all out chasing your hobbies. If you have a camera collecting dust somewhere here is your opportunity to make good use of it as Royal Society announces photography competition. And those who used to fond of writing but now haven’t pursued it for a while, learn how to be creative on purpose?!s A lot of us on Club SciWri might vouch for its success. Here is some advice that works for Susan Cain in helping herself put her thoughts out in and for public in writing. We can all do it, if Precilla D’Souza could finish her PhD in the face of terminal cancer.

And let me end for the day with some Sunday humor – have you ever wondered what would it look like if corporate incorporated grad school mannerisms? If you are one those who think that would be a wonderful world, read this. If you don’t think so, read it anyway for a big grin 🙂

About the author:

Somdatta Karak works with Club SciWri as a project coordinator and Corporate Liaison. She is a doctorate in Neuroscience from Georg August University, Göttingen, Germany and has been a Teach for India fellow (2014-16). She loves putting her analytical skills to build newer and more sustainable solutions, enjoys traveling and communicating and takes every opportunity to expand her horizon.

You can reach her here.

 

The week that it was – 8th to 14th May, 2017

in ClubSciWri by

This Mother’s day, going beyond the commercial reasons behind existence of such a day, CSG and Club SciWri celebrate the mothers of many a scientific discoveries. Let’s use this as another opportunity to remind ourselves of gender inequalities that exist around us in academia and beyond, and appreciate efforts by groups like Million Women Mentors in STEM, and Healthcare Businesswomen’s Association.

Earlier this week, Europe reassured that they still are away from far-right ideologies. And not only this comes as a reassurance in the wake of US, UK and Turkish elections and growing Nazi-like inclinations in India, the newly elected French president, Emmanuel Macron has also assured support to climate change researchers. Europe, is probably, going through its best time to regain its older glory in scientific research and development by collaboration. Why collaboration? To translate grand ideas into reality – like the bipolar disorder researchers have analyzed roughly 9000 human brains worldwide.

For us to remember in our race for power, by Ipsa Jain (her work at IpsaWonders, on Facebook and Instagram)

That also calls us, the scientists into action for making sure that we are able to convey our messages correctly to public – it is an art to not over-simplify science and yet be able to reach masses, through the power of words. You might even want to consider applying for a summer school in learning the art of science communication by ASBMB. And if you need inspiration, get some from the geniuses like Carl Zimmer.

Patience is a virtue for innovators, one that hasn’t changed since the last 30 years, when the first 3D printer was made, or when Daniel Martinez first noted that hydra do not die to the present day often heard biotech startup failures or the success of newer drugs in increasing the life spans of HIV positive individuals to near normal.  Not every idea is necessarily successful, rather growing while learning from the failures is the skill that we need. In this current age, nothing values more than data. The amount of data that an organization can gather and analyze marks its success. It will be interesting to see how governments work around the big private enterprises that virtually monitor most of us. And there is someone else too, who is getting unsettled with data sharing – science publishing houses. Nature news reports that publishing houses are building strategies to cope up with the increasing trend of sharing paywalled papers. But until that happens, as sad it might be, you can technically get into legal troubles by sharing scientific research articles. Do your bit by speaking up for open access research – OpenCon is one such platform to get yourself educated and heard on open access.

Choose a mentor first, lab next – it helps to ensure both personal and professional growth. But unfortunately, since this isn’t followed by many yet, a lot of us stay confused how will our research advisors react to our possible decisions of transitioning into industry. Read Catherine Sorbara’s opinion on how industries do not care to get academic recommendation letters. Beyond graduate schools, future employers will want to have references, not recommendation letters. And they aren’t the same thing – see what’s different! Know what and how to discuss matters with employers and colleagues. A loose word can cost a lot. And know how to keep your focus on your existing job while you plan your transitions. Accessing these resources to learn is much easier these days. Be spoiled for choice rather to know what you would like to pursue among the list of online courses. Those working in bio/pharma discovery should consider Global BioPharma Summits to stay abreast the rapidly changing trends in the field.

Skim through the works of 41 international biomedical researchers who just got awarded by well-known philanthropies – it might help you as well to know what are the topics trending in the field. 26 biotech startups  in Karnataka, India are awarded funding by the state government. I hope that has gotten your brains active and you are ready to fish out where you see yourself in the coming years.

And then there are freelancers who can mix and match quite a few of these together, quite successfully, eventually with practice! Wonder if you have the right credentials to do it all? Count your relevant experience rather.

Those aspiring for MSL positions, might also consider attending the 2017 MSL Society Candidate Career Conference in North Carolina, USA from June 10-11 – Use the opportunity well for networking with hiring managers. Those who are lost on how to prepare for the HR interviews, here is a great resource. See what are the skills that the big pharma companies look for in their new recruits. Those who are not yet sure if a formal MBA course is what they are interested in, but still might want to gain some education into it, might want to consider the micro-MBA course at UCSD this summer. For the enterprising entrepreneurs, here is a dose of inspiration from Regeneron, on their path from basic research to commercialization.

Now we understand knowing which job suits you the best isn’t an easy job. But one has to start somewhere, sometime! At the same time, know the tricks to look and apply for jobs outside academia, if that is where your heart is.

And since I promised the last time that I will keep you all updated on the out-of-lab activities that you can indulge in this summer – check the live radio streaming worldwide, you might like some light music running while you are busy with your experiments. And because many of us at CSG are also keen on building a library of Goodreads in Science, there is one out by Prof. Jennifer Doudna and her former postdoc, Samuel Sternberg on gene editing by CRISPR, called ‘A crack in the creation‘.

And let me leave you with a food for thought – While India in her pre- and early post-independence days created the stalwarts in science from the likes of Raman to Ramachandran, how does the country still struggle coping up with scientific development when compared to many of her peers like China? Does the answer lie in simply better management of resources and adding accountability? If so, how might that be achieved? Read Prof. Gautam Desiraju’s latest opinion surrounding this.

Featured images are by Ipsa Jain, a Ph.D. student at IISc. She wants to gather and spread interestingness. She prefers painting and drawing over writing. She posts on Facebook and Instagram as Ipsawonders.

About her featured cover image: (From left to right) Shown are Sally Ride, Ada Lovelace, Maria Sibylla Merian, Henrietta Swan Leavitt, Hilde Mangold, Barbara McClintock in celebration of Mothers of Science by Club SciWri.

About the author:

Somdatta Karak works with Club SciWri as a project coordinator and Corporate Liaison. She is a doctorate in Neuroscience from Georg August University, Göttingen, Germany and has been a Teach for India fellow (2014-16). She loves putting her analytical skills to build newer and more sustainable solutions, enjoys traveling and communicating and takes every opportunity to expand her horizon.

You can reach her here.

MedNess: FDA approvals,rejections, M&A and more…

in Medness/SciBiz by

 

Illustration: Ipsa Jain

Hello and welcome to MedNess where we bring you the news from healthcare market. We are excited to announce the brand new section known as MedNess Focus, led by Abhinav Dey, Ph.D. that will be published every alternate week. Stay tuned for that next week where he will “Focus” on Novartis’ CAR-T therapy BLA! We are also excited to introduce MedEurope this week, led by Czuee Morey, Ph.D. For other in-depth coverage, please subscribe to @Club SciWri (www.sciwri.club)

FDA grants approval to Gilead Hep C drugs for pediatric patients
The U.S. Food and Drug Administration granted approval to supplemental applications for two Hep C drugs; Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) for use in pediatric population ages 12 to 17 or weighing at least 35 kg. The drugs are approved to treat hepatitis C in adolescents without cirrhosis or with compensated cirrhosis. Harvoni gained approval for treating pediatric patients with genotype 1, 4, 5 or 6 hepatitis C virus (HCV), while Sovaldi was approved for treating pediatric patients with genotype 2 or 3, in combination with ribavirin. Both of these drugs were previously approved to treat hepatitis C virus (HCV) in adults. The supplemental approval came in as a win for both the medical field and business investment field. These two drugs are the direct-acting antiviral agents approved for the pediatric patients. Direct acting antivirals are efficient in curing HCV in most cases. These agents prevent the virus from multiplying thus reducing the amount of HCV in the body. Alternatively, the supplemental approval of Sovaldi  and Harvoni  also came in as a relief to the slumping Gilead sales (Fierce Pharma)

MedNess: Gilead Sciences tops HCV and HIV treatment market. However; recently, the patent battles and competition from the rivals has given tough time to Gilead’s stocks. While investors have been worried about Gilead’s cranking cash flow, the expanded label approval of Gilead Sciences star HCV drugs; Sovaldi and Harvoni should provide a sigh of relief. There was a slight increase in the stock price after the expanded drug approval use (seeking alpha and The Motley Fool).

FDA rejects Merck’s plea to drop cardiovascular risks from sitagliptin label
The FDA sent a complete response letter to Merck rejecting the drug maker’s appeal to include outcomes from its TECOS trial. This heart study showed that Merck’s drugs used for the treatment of diabetes; Januvia and its related combos Janumet and Janumet XR had “no signal” of heart failure (FiercePharma).

MedNess: Merck has been facing competition with Eli Lilly’s and Boehringer Ingelheim’s SGL2 medicine Jardiance and Novo Nordisk’s GLP-1 Victoza which have shown to reduce the combined risks of heart attack, stroke, and death from the cardiovascular disease. Amongst these rivals, Merck wanted to follow suit. The stock prices of Merck fell after the letter on Friday (Investor’s.com).

FDA authorizes 23andMe Personal Genome Service Genetic Health Risk tests
The FDA approved the marketing of genetic health risk analysis. The results of these tests will provide information directly to customers without requiring physician’s prescription.
The genetic health risk tests can detect a genetic predisposition to 10 diseases including Parkinson’s disease, late-onset Alzheimer’s disease, and Gaucher disease. But there are certainly gray areas with the testing system. The tests are designed to provide information on genetic predisposition that can help make lifestyle changes, but the results are not expected to be entirely valid or “fully penetrant.” This implies, even if a person is shown to be at higher risk genetically, he or she might never develop a disease in their lifetime and vice versa. In addition, the reports provided by these test results will be independent of the family history. This is particularly concerning as for some diseases; family predisposition might increase the risk in general. Therefore, customers are advised beforehand to not to rely on the test results completely and not to get emotionally upset with the unfavorable test results (STAT).

NIH’s Zika vaccine enters Phase 2 trial amongst budget cut frenzy
The Phase 2 trial testing a Zika vaccine, developed by scientists at the National Institute for Allergy and Infectious Diseases (NIAID), began at Baylor College of Medicine in Houston. The phase 2 study results are expected by the end of this year.
The clinical trial involves a DNA-based vaccine, lacking a live Zika virus, but from which proteins are placed into small pieces of DNA. NIAID is a part of the NIH and is obviously affected by President Trump’s recent budget proposal cut. However, given the importance of this study, the institute has dedicated $100 million funding for the Phase 2 work. If the Phase 2 study is successful, NIAID will partner with commercial sources to bear the costs of larger Phase 3 trials (STAT)

Novartis CAR-T therapy BLA granted FDA priority review
Novartis announced that the US Food and Drug Administration has accepted the company’s first Biologics License Application (BLA) filing and granted the priority review for CTL019 (tisagenlecleucel-T) in relapsed and in relapsed and refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). CTL019 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy.  The priority review designation is expected to shorten the anticipated review time to six months.

In the Phase II ELIANA study, 82% (41 of 50) of patients infused with CAR-T cells achieved either complete remission or complete remission with incomplete blood count recovery after three months. The study enrolled patients globally across the US, EU, Canada, Australia, and Japan.

CAR-T therapy, one of the most controversial treatments involving gene therapy, utilizes reengineered patient’s T cells. These T cells (immune system’s killer cells) are filtered from patients blood and altered in the lab and injected back intravenously making it a “living drug.”(Novartis.com)

MedNess: After the announcement, Novartis shares were little changed but the shares of the company making CTL019 raw materials, Oxford BioMedica, rose by more than 4.5 percent. Alternatively, Kite Pharma, Novartis’ rival in CAR-T race, also submitted a rolling application for their chimeric antigen receptor T cell candidate. Rolling applications are allowed for promising new drugs. Kite’s application could be accepted early putting behind Novartis’. Therefore, the winner of the CAR-T race will set the price of the therapy and subsequently the stocks (Reuters and Nasdaq).

MedEurope by Czuee Morey, Ph.D.

Astellas Pharma expands its portfolio to women’s health by acquiring Belgian biotech Ogeda
Japanese Astellas Pharma announced its plans to acquire privately owned, clinical-stage drug discovery company Ogeda. The acquisition comes three months after Ogeda achieved positive results from a Phase IIa study of fezolinetant (ESN364), its lead drug candidate. Fezolinetant is a potential non-hormonal treatment for menopause-related vasomotor symptoms (MR-VMS) such as hot flushes and night sweats and is an antagonist of the GPCR known as tachykinin receptor neurokinin3 (NK3). The phase II data showed statistically significant reduction in both frequency and severity of menopausal hot flushes versus placebo in 80 women.
Astellas’ offer consists of €500 million ($530 million) upfront followed by an additional €300 million ($318 million) if Ogeda meets its development and regulatory milestones. Astellas will also benefit from a few pre-clinical assets under investigation for autoimmune diseases and ulcerative colitis. The companies expect the deal to close in the second quarter, at which point Ogeda will serve as an Astellas subsidiary. This acquisition will help to expand Astellas’ pipeline that is primarily focused on oncology.

MedNess: The global MR-VMS market was valued at US$3.77 bn in 2014 and is projected to grow at a CAGR of 3.7% from 2015 to 2023 to reach US$5.28 bn by 2023. Ogeda is also running Phase II trials with the lead candidate to treat polycystic ovary syndrome (PCOS) and uterine fibroids. Other companies developing neurokinin antagonists are UK based NeRRe Therapeutics for a range of conditions from sex hormone imbalances to opiate use and US-based Millendo Therapeutics for polycystic ovarian syndrome, both in Phase II.
Astellas stock, which trades on the Tokyo Stock Exchange, was up about 2% to ¥1,492 ($13.39) on Monday morning after the announcement.
(PRNewsWire, Labiotech.eu, Seeking Alpha)

About the author:

Imit Kaur is a freelance medical writer, editor and an active science blogger. She pursued her PhD in Pharmaceutics and Pharmaceutical Chemistry from University of Utah. She is experienced in the field of oncology, hematology, pharmacology, nanotechnology and drug development.

 

MedNess- Immuno Oncology, Precision Medicine and more….

in SciBiz/Uncategorized by

Picture Illustration: Ipsa Jain

CAR-T therapy- a step closer to precision medicine?

Kite Pharma’s CAR-T candidate axicabtagene ciloleucel (previously referred to as KTE-C19) might be the first gene therapy to gain approval from FDA. The candidate therapy attained primary endpoints in a major study. The study encompassed patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma. The study showed that out of 101 patients enrolled in ZUMA-1 trial, 82% had their cancer shrunk at least by half after six months. In addition, 41% had partial response while 36% of patients went on complete remission. The therapy comes with its own share of risks. 3 patients in the study died and 2 of the deaths were attributed to the treatment.

CAR-T therapy, one of the most controversial treatments involving gene therapy, utilizes reengineered patient’s T cells. These T cells (immune system’s killer cells) are filtered from patients blood and altered in the lab and injected back intravenously making it a “living drug”.

Novartis and Juno Therapeutics are also in the race for CAR-T therapy. However, Juno Therapeutics announced the discontinuation of their experimental product early this month. This is because thirteen percent of patient deaths were reported, majorly due to cerebral edema and brain swelling. Kite Pharma’s CART-T cell product is safer in this regard. Kite Pharma’s axicabtagene ciloleucel was granted Breakthrough Therapy Designation status for diffuse large B cell lymphoma, transformed follicular lymphoma, and primary mediastinal B-cell lymphoma by the FDA and by the Food Priority Medicines (PRIME) regulatory support for DLBCL in the EU.

MedNess: Although Kite Pharma has not presented formal results of the trial and is expected to present their report at the annual conference of American Association of Cancer Research in April this year, the reports of axicabtegene ciloleucel meeting primary endpoints raised the stock prices by 13% of this California-based biopharmaceutical company. Kite Pharma’s CAR-T product might be first in line to gain approval from FDA by the end of this year leaving behind the products from its competitors. Therefore, stocks of Kite Pharma hold a lucrative future. However, a lot can change in further studies and it all comes down to safety and efficacy of the final product (FiercePharma, STAT).

Barclays analyst’s stern advice to Gilead Sciences

Geoff Meacham, Barclays senior analyst apparently lost patience with Gilead Sciences, urging it to “do something”. He sent an open letter to the management prompting the company to either make an acquisition or take strict measures to improve sales and profit growth. Meacham suggested measures including Gilead’s orphan drugs diversification, cost cutting in Hep-C business due to declining market, HIV franchise clarification and/ or in-licensing deals in order to gain trust of its investors (Seekingalpha)

MedNess: Gilead Sciences sales and profit growth have eroded as its hepatitis C franchise has declined, the shares have slipped by 1% and profits have declined in each of the past five quarters.

Scott Gottlieb to lead FDA under Trump administration

Scott Gottlieb who has served as a practicing physician, clinical assistant professor at New York University and health information technology adviser for the department of Health and Human Services, has been selected as Trump’s nominee to lead FDA. The president’s selection is expected to yield support from biopharma industry. Gottlieb, if confirmed, is likely to hasten the drug approval process that might have earned him Trump’s support. He was a former deputy commissioner for medical and scientific affairs at the FDA under George W. Bush (FiercePharma).

Earlier this month, Club SciWri initiated a new section on Science and Policy, emphasizing on the involvement of scientists in the healthcare policy decisions. Gottlieb’s nomination to lead FDA will serve as a perfect example, underscoring the relevance of this sensitive subject.

BMS appoints Thomas Lynch as its new Chief Scientific Officer

BMS has been in news for quite a while now and that too for all the wrong reasons. Amongst the turmoil and speculations of its buyout, BMS appointed Thomas Lynch as its new Chief Scientific Officer (CSO) while the former CSO Francis Cuff made the exit this Wednesday. Thomas Lynch, an oncologist, was a former board member of BMS. With the new appointment, hopes are high on the Opdivo front as well. Recently, Opdivo fell short in a major clinical trial when tested on previously untreated lung cancer patients. Opdivo is PD-L1 checkpoint inhibitor and therefore its efficacy is expected to be better in patients with higher levels of this biomarker. However, BMS lost its non-small cell lung cancer lead to rival Merck’s Keytruda that succeeded in patients with a PD-L1 score of 50% or more. Also, earlier this year, BMS decided to not to seek accelerated approval for their Opdivo-plus-Yervoy combination in lung cancer. These two events combined with new checkpoint inhibitors expected from Roche, AstraZeneca, Merck and Pfizer have put BMS’s shares down. However, analysts suggest, BMS share might still be a great bargain if the drug succeeds in other arms of the trial, testing Opdivo as a monotherapy in first-line lung cancer. The company also awaits readouts from Phase 2 and Phase 3 studies evaluating Opdivo and Yervoy in other types of cancer (FiercePharma, The Motley Fool).

 

MedNess-Pill for Alzheimer’s?

in ClubSciWri/SciBiz/Uncategorized by

Hello and welcome to yet another exciting week of MedNess. We bring the news from medicine and healthcare with greatest impact. It seems like; year 2017 will be the year of neurology! It is just the second month of the year and treatment strategies for various neurological disorders are making headlines.

Merck halts Phase 3 study on Alzheimer’s drug- another setback for amyloid theory

Clinical trials on Verubecestat- a small molecule BACE 1 and BACE2 inhibitor were called off after an interim analysis on Phase 2/3 studies did not show promising results. The analysis team concluded that there was “virtually no chance of finding a positive clinical effect”. However, another trial on patients with early symptoms of Alzheimer’s will continue. It has been speculated that the drug was too weak, or was dosed inadequately or the disease had progressed too far in patients for the drug to show concrete effect. The failure of this trial is another blow to the famous “amyloid theory”. According to this theory, the amyloid plaques are believed to be cause of the disease. Verubecestat is a beta secretase inhibitor. This disappointing cessation of clinical trial came months after Eli Lilly’s Alzheimer’s drug; Solanezumab failed in Phase 3 clinical trials in November last year. Unlike Verubecestat, Solanezumab targets plaque rather than beta secretase enzyme. This brings in disappointment not only for the patients but also for the researchers. The evidence suggests that once the disease has advanced and patients have established dementia, the removal of amyloid plaque might not yield effective outcome.

                              Do we have a pill to cure Alzheimer’s? Some quick facts:

  • Alzheimer’s is an irreversible brain disorder causing cognitive impairment
  • More than 5 million Americans are expected to suffer from Alzheimer’s
  • Sixth leading cause of death in the USA
  • No new drug has been introduced to provide symptomatic relief or to halt its progression since last decade

Picture source: https://unsplash.com/search/brain?photo=rmWtVQN5RzU

There are couple of drugs at various stages of trial that are being tested under the amyloid plaque hypothesis. These drugs either act on the plaque or beta secretase enzyme (BACE inhibitor) or available as amyloid immunotherapy. These candidate drugs are from Biogen, AstraZeneca, Eli Lilly, Amgen and Novartis. Apart from BACE inhibitors, hopes are also high for Axovant’s intepirdine. Intepirdine is believed to improve cognitive symptoms by targeting receptor 5-HT6 that stimulates the release of a neurotransmitter. Interestingly, intepirdine was abandoned by GSK in 2010. The drug failed when compared to placebo. However, one study showed tangible effect on cognitive symptom when intepirdine was paired with the approved Alzheimer’s drug Aricept.

MedNess: Merck’s stock suffered severe blow after the announcement of cessation of clinical trial. On the contrary, shares of Eli Lilly, AstraZeneca, Biogen and Roche, the fellow Alzheimer’s drug makers, increased. (Fierce Biotech, Business Insider, STAT news, The Boston Globe)

Axovant’s nelotanserin passes phase 2 study for Lewy body dementia

Axovant Sciences declared successful completion of phase 2 study of nelotanserin. The company is now setting its foot forward for phase 3 study that is expected to initiate later this year. Axovant Sciences reported preliminary results from the first small group of 11 patients.

Lewy body dementia or LBD is the second most common form of dementia. The hallmark characteristic of this form of dementia is the build up of abnormal proteins i.e. Lewy bodies thus affecting cognition, movement, behavior and alertness.

The study included patients with either LBD or Parkinson’s disease dementia. These patients experienced frequent hallucinations as assessed by mini mental state examination (Pharmaceutical Business Review)

CRISPR battle of patents: The Broad institute and MIT wins!

The scientists who first demonstrated the use of most powerful gene editing technology in biotech suffered a major blow on Wednesday, February 15, 2017, in their fight to gain exclusive rights on their invention. CRISPR gene editing system has revolutionized the field of biotechnology enabling scientists to make changes in DNA. Jennifer Doudna, a UC Berkely biochemist and her European collaborator Emmanuelle Charpentier first published this gene editing technology in prokaryotic system (type of bacterial system) in 2012 in Science. UC Berkely and University of Vienna filed for U.S. patent in March 2013. There were 155 broad claims to the CRISPR-Cas9 technology. Feng Zhang, a biologist at the Broad Institute, demonstrated the use of this technology in eukaryotic cells (type of plant cells, animal cells and human cells). The Broad Institute filed their patent in 2013; months after Berkeley group filed their patent. Since the patent claims by Broad Institute were fewer than Berkeley’s, the Broad Institute’s patent was issued on April 15 2014 through accelerated approval while Berkeley group is still awaiting their approval. After the Broad Institute was granted their patent, UC Berkeley filed an interference claiming that the Broad Institute should not have been granted the patent since Doudna’s and Charpentier’s CRISPR research outlined in 2012 paved the way for Zhang’s research in eukaryotic system. The Broad Institute argued that the research was not obvious and the patent claims from both the institutes were different. The federal Patent Trial and Appeal Board ruled out UC Berkeley’s claims and sided with the Broad Institute. With this decision, UC Berkeley plans to move forward with their patent application, which if approved, will provide them right on the use of CRISPR on all cells. This would also mean that if the technology will be employed commercially, the companies would have to get licenses from both the Broad and the Berkeley group.

MedNess: The patent decision in the favor of the Broad institute increased the stocks of Editas Medicine by 30%. Editas Medicine licenses Broad’s patents for human genetic disorders. (Fierce Biotech, STAT News, The LA Times, NPR, Wired)

Are pharmaceutical industries in favor of Trump’s FDA pick? The story so far….

Donald Trump is pushing deregulation of FDA in order to accelerate the drug approval process. His ideology: drug costs are higher, drug approval process through FDA takes forever, drug companies are involved in “unfair foreign trade”, drugs should be manufactured in the USA and finally, drug companies should add the innovation factor for the better cure of the diseases. This recipe will work in favor of patients to bring the overall drug costs down and patients can have quicker access to the newer agents. Not to forget, drug manufacturing in the USA brings back jobs and the “fair trade” promotes revenue generation. This all sounds good, except, the pharmaceutical industries have opposing views. The most common complaint of every patient and every healthcare researcher is the never-ending drug approval process by the FDA. So suddenly, when we might be able to overcome this hurdle, why is everyone (read the researchers, pharmaceutical companies and informed patients) so anxious? The truth is bitter sweet. Even though we rant over the FDA, we still knew, the FDA has best interests at heart and such a tight screen is probably important for the safety of the patients. In addition, a 2011, study found that the FDA usually approves cancer drugs before Europe does. Moreover, the researchers at Yale found the FDA’s drug review is at least a month faster than Europe’s or Canada’s.

The pharmaceutical industries on the other hand are concerned about the high drug costs. In addition to the limited patient safety, deregulation in the FDA might not provide enough time for pharmaceutical companies to justify high costs of the drugs to patients and to insurance companies. The pharmaceutical companies will not be able to account for high costs of the drugs owing the limited safety and efficacy analysis that ultimately affects both the patients and the companies. President Trump said last month he has a “fantastic person” lined up for the role of the FDA commissioner. A survey conducted by Mizuho Securities of drug company executives indicated that 72 percent agreed Scot Gottlieb should be Trump’s pick to head the FDA. Until then, we all wait! (Reuters, The New York Times, Forbes)

 

              

MedNess- At the frontier of Medicine, Pharmaceutical and Healthcare Business

in Poli-Scie/SciBiz/Uncategorized by

Hello and welcome to the biweekly roundup of Healthcare business top stories. Please follow us on Twitter and LinkedIn

MedNess 

BMS’s injectable Opdivo approved by FDA for bladder cancer

FDA approved intravenous use of Opdivo (nivolumab), a PD-1 checkpoint inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have not benefitted from platinum-containing chemotherapy or in cases where the disease progressed within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. Last year, FDA approved Roche’s Tecentriq, a checkpoint inhibitor, for the treatement of bladder cancer.

From the business standpoint, this was much awaited good news for BMS as the Opdivo did not make the cut as first line monotherapy study in non small cell lung cancer (NSCLC) in 2016. However, Merck’s Keytruda gained FDA approval soon after Opdivo failed in NSCLC study (Fierce Pharma).

 

The battle of patents: bad news for Teva Pharmaceuticals

Genric drug maker giant: Teva Pharmaceuticals lost the patent challenge in U.S. District Court, safeguarding their star drug Copaxone against generic competition. Copaxone, approved in 1996, became the most prescribed drug for the treatment of multiple sclerosis. The patents protecting Copaxone against generic competition expired two years ago for 20mg dose. Novartis and Momenta launched their 20 mg alternative (Glatopa) in 2015. To recuperate, Teva launched a 40 mg formulation of Copaxone. However, this week, U.S. District Court invalidated Teva’s last and fourth key patent protecting 40 mg Copaxone from generic drug competition. Teva lost other 3 patents last year (Madison.com).

Trump pledges to bring drug costs down

Pharmaceutical industries were told by Trump that the drugs should be manufactured in the USA and the foreign countries buying US manufactured drugs should pay “fair share”. These changes in addition to “better innovation” will help bringing prices down for the US patients (CNBC).

MedNess from MedPol: Amgen CEO Robert Bradway announced that soon nearly 1600 jobs will be added. Bank of America Merrill Lynch predicted that Trump’s policies could help Amgen recover their stocks by 23% in the next 12 months (CNBC)

MedPol

US President’s executive order on immigration: the aftermaths

This is not a political blog, but the executive order has a very significant impact on the scientific, medical and healthcare community. In the following paragraphs, I will brief you with the sectors that have been affected.

  • NRMP issues the statement for the upcoming Match

Nearly 260 people from seven nations affected by travel ban, applied through National Resident Matching Program (NRMP) for medical residency in the USA (Association of American Medical Colleges, AAMC). Both the applicants and the hospital programs are concerned and affected by the travel ban. However, NRMP has urged the programs and the applicants to be discrete in their decisions that are in the interest of healthcare. The official statement issued by NRMP on their website states, “The medical education community must support all international medical graduates and their families during these difficult times. As for the current Match cycle, NRMP encourages applicants and programs to make the best decisions they can under current circumstances. For its part, NRMP will be liberal in granting waivers to applicants and programs if they cannot meet their respective Match obligations because of the effects of the Executive Order” (NRMP.org).

  • Dark times for the US hospitals and patients from seven nations affected by travel ban

Ill patients scheduled for treatment at the USA’s premier healthcare centers, John Hopkins Medicine and Cleveland Clinic are uncertain of their treatment options. Hopkins is taking a step ahead by either urging the patients to postpone their travel or sending their staff abroad for their treatment (STAT News)

We wrap up our biweekly MedNess and MedPol news section. Have a great weekend!

Image source: https://unsplash.com/search/medicine?photo=nss2eRzQwgw

Go to Top
Close
loading...
%d bloggers like this: